Source: LIVEMINT

Clonz Biotech: For Clonz Biotech, biosimilars promise high rewards, high risks

CEO Narasimha Rao Nedunuri and his team synthesized two key biosimilar molecules, Rituximab and Trastuzumab

Read full article »
Clonz Biotech's Competitors | Clonz Biotech's News | Clonz Biotech's Financials
Stay up-to-date with the latest news on Clonz Biotech
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Narasimha Rao Nedunuri's photo - Managing Director of Clonz Biotech

Managing Director

Narasimha Rao Nedunuri

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Clonz Biotech